Back to search results

CuidaTEXT for Latino Caregivers of People with Alzheimer's Disease

This study is testing a new text message program called CuidaTEXT for Latino caregivers of people with Alzheimer's disease and related dementias (ADRD). CuidaTEXT is a 6-month program that sends daily text messages in both Spanish and English. These messages cover topics like ADRD education, social support, self-care, managing care, and behavioral symptoms. The goal is to see if CuidaTEXT can help reduce stress and negative feelings for caregivers. You may be able to join if you are over 18, identify as Latino, speak Spanish and/or English, and provide hands-on care for a relative with an ADRD diagnosis and cognitive impairment. The study will measure changes in caregiver depressive symptoms over 6 months. The current recruitment status is unclear.

Study design
This is a randomized clinical trial, meaning participants will be assigned by chance to either receive the CuidaTEXT program or not. The study plans to enroll 288 participants.
What's involved
Participants will receive text messages for 6 months and complete surveys about their depressive symptoms, coping, behavioral symptoms, and preparedness for caregiving.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months, as depressive symptoms are measured at baseline and 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06728436

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

Recruiting
NAAges 18+InterventionalSupportive care
University of Kansas Medical Center
~288 participants
Updated 2025-12-11 on ClinicalTrials.gov
What's tested:CuidaTEXT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in caregiver depressive symptoms
Measured over Baseline and 6 months

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's Disease

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Jaime Perales Puchalt, PhD, MPH · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center

Who to contact

Rachel Ruiz
[email protected]
913-945-5052
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Over the age of 18
Spanish and English-speaking people who identify as Latino
Reports providing hands-on care for a relative who has been given a clinical or research ADRD diagnosis and has an Eight-item Informant Interview to Differentiate Aging and Dementia (AD-8) screening score ≥2, indicating cognitive impairment
Has a score of 7 or higher on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10)
Self-reports being able to read and write
Owns a cell phone with a flat fee, and uses it at least weekly for texting.

Exclusion

Participation in another wellbeing-related clinical trial
Cohabitation with another participant in the CuidaTEXT R01 Study
Participants who provide care for a person with ADRD already cared for by another participant in the CuidaTEXT R01 study
Participant plans to move to another country within seven months

What this trial measures

  • Change in caregiver depressive symptomsBaseline and 6 months

    Change in caregiver depressive symptoms from baseline to 6 months as measured by the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10). The CES-D-10 is a self-report rating scale that measures characteristic symptoms of depression in the past week (e.g. depression, loneliness). Each item is rated on a 4-point scale (Rarely or None of the Time-Most or All of the Time). The summary score ranges from 0 to 30 with higher scores indicating higher severity.